Compugen Earnings Call Transcripts
Fiscal Year 2026
-
The discussion highlighted a unique computational platform for early-stage target discovery in immuno-oncology, emphasizing rigorous validation, clinical translation, and strategic flexibility. Key milestones include the MAIA-ovarian study readout in Q1 2027 and ongoing partnerships with major pharma companies.
-
AI-driven immuno-oncology discovery has led to a robust pipeline, including COM701 in pivotal ovarian cancer trials, GS-0321 in partnership with Gilead, and rilvegostomig with AstraZeneca in 11 phase III studies. Recent monetization and milestones provide financial runway into 2029.
-
Q1 2026 saw continued clinical and financial progress, with COM701 and partnered assets advancing in trials and a strong cash position supporting operations into 2029. Interim MAIA-ovarian trial data is expected in Q1 2027, and new rilvegostomig data will be presented at ASCO.
-
The company showcased its AI-driven immune-oncology pipeline, highlighting COM701 and rilvegostomig, with major partnerships and robust financials. Key trials target platinum-sensitive ovarian cancer and innovative bispecific antibody strategies, with pivotal data expected from 2027 onward.
-
AstraZeneca's rilvegostomig is being tested in 11 phase III trials, leveraging a bispecific, Fc-reduced format and novel biomarker-driven combinations, with key readouts expected after 2027. COM701 is being evaluated in platinum-sensitive ovarian cancer, and an IL-18BP program with Gilead is advancing in phase I.
-
COM701 is advancing in a randomized trial for platinum-sensitive ovarian cancer, aiming to extend progression-free survival, with interim data expected in Q1 2027. Partnerships with AstraZeneca and Gilead provide financial stability and support a robust early pipeline focused on novel immuno-oncology targets.
Fiscal Year 2025
-
Cash runway extended into 2029 after a $65M AstraZeneca deal, with strong 2025 revenue growth and a shift to net profitability. Key clinical programs advanced globally, with major data readouts expected in 2027 and significant milestone potential from partnerships.
-
The company highlighted its AI-driven immuno-oncology pipeline, including COM701 for ovarian cancer and GS-0321 for cytokine modulation, both advancing in clinical trials. Strategic partnerships with AstraZeneca and Gilead provide significant milestone and royalty opportunities, with a cash runway into Q3 2027.
-
Solid cash position supports operations into Q3 2027, with key clinical programs advancing and major catalysts expected in 2026. Revenue declined year-over-year due to milestone timing, while R&D and G&A expenses decreased. Clinical data and partnerships with AstraZeneca and Gilead drive future value.
-
Leadership transition and a focus on AI-driven immuno-oncology mark a new phase, with a robust pipeline, major pharma partnerships, and strong financials supporting growth. Key clinical readouts and milestone opportunities are expected in the next few years.
-
The company leverages its Unigen™ AI platform to discover novel immuno-oncology targets, advancing assets like COM701 and COM902 through strategic partnerships with AstraZeneca and Gilead. The MAIA ovarian cancer study is a key focus, with interim results expected in 2026. Financially, a $94M cash position supports operations into 2027.
-
Leadership transition and strong cash position support ongoing clinical progress in immuno-oncology, with key trials advancing and major partnerships offering significant milestone potential. Revenue declined year-over-year due to milestone timing, but cash runway extends into 2027.
-
Leadership transitions and a strong cash position support ongoing clinical and early-stage immuno-oncology programs. Q1 2025 saw stable net loss and lower R&D expenses, with key trials advancing and significant partnership milestones possible from AstraZeneca and Gilead.
-
The company is advancing its AI-driven immunotherapy pipeline, with COM701 in a pivotal adaptive trial for platinum-sensitive ovarian cancer. Strategic partnerships, notably with AstraZeneca, and a strong IP position support growth, while ongoing platform innovation aims to expand the pipeline.
-
The presentation detailed a robust immuno-oncology pipeline driven by computational discovery, with key assets advancing in ovarian cancer and TIGIT-targeted therapies. Strategic collaborations with AstraZeneca and Gilead provide significant milestone and royalty opportunities, while adaptive trial designs address unmet needs in cancer care.
-
The company leverages AI-driven discovery to advance first-in-class immuno-oncology assets, with major partnerships and clinical programs underway. Key deals with AstraZeneca and Gilead provide significant milestone and royalty potential, and a strong cash position supports operations into 2027.
-
The discussion highlighted a robust immuno-oncology pipeline driven by computational discovery, with key assets advancing through strategic partnerships and innovative trial designs. Notable progress includes AstraZeneca's rilvegostomig in phase 3, adaptive trials for COM701 in ovarian cancer, and a novel IL-18BP program with Gilead.
-
Recent data show durable responses for triplet therapy in platinum-resistant ovarian cancer, supporting the move to a COM701 monotherapy trial in platinum-sensitive patients with a targeted 50% PFS improvement. Strategic partnerships with AstraZeneca and Gilead advance pipeline assets, with significant milestone and royalty potential.
Fiscal Year 2024
-
Key 2024 milestones included advancing COM701 and GS0321, with strong cash reserves of $103.3M and a runway into 2027. Revenue declined year-over-year, but milestone payments from Gilead and AstraZeneca supported operations. Interim data for COM701 is expected in 2026.
-
Recent data show durable responses and good safety for triplet therapy in platinum-resistant ovarian cancer, with a new trial of COM701 monotherapy in platinum-sensitive patients set to begin soon. Pipeline progress includes a phase 1 start for COM503 and ongoing partnerships with Gilead and AstraZeneca.
-
Q3 2024 saw strong financial performance with $17.1M in revenue and a $1.3M net profit, driven by milestone payments and reduced R&D expenses. Clinical data confirmed durable, well-tolerated responses for COM701 combinations in ovarian cancer, supporting a new maintenance therapy trial in 2025.
-
The session highlighted a robust immunotherapy pipeline, strategic partnerships, and promising clinical data in hard-to-treat cancers. Key milestones include a strong cash position, upcoming trial results, and major data presentations by partners in Q4 and September.
-
Q2 2024 saw FDA IND clearance for COM503, a $30M milestone, and strong cash position. Revenue rose to $6.7M, net loss narrowed, and key clinical data in ovarian cancer is expected in Q4. Partnerships and pipeline advances support a positive outlook.